- Home
- CLRB vs BNC Comparison
CLRB vs BNC Comparison
Compare CLRB & BNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- BNC
- Stock Information
- Founded
- CLRB 2002
- BNC N/A
- Country
- CLRB United States
- BNC United States
- Employees
- CLRB N/A
- BNC N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- BNC Industrial Machinery/Components
- Sector
- CLRB Health Care
- BNC Industrials
- Exchange
- CLRB Nasdaq
- BNC Nasdaq
- Market Cap
- CLRB 14.2M
- BNC 13.7M
- IPO Year
- CLRB N/A
- BNC N/A
- Fundamental
- Price
- CLRB $4.98
- BNC $17.07
- Analyst Decision
- CLRB Hold
- BNC
- Analyst Count
- CLRB 2
- BNC 0
- Target Price
- CLRB N/A
- BNC N/A
- AVG Volume (30 Days)
- CLRB 154.8K
- BNC 343.8K
- Earning Date
- CLRB 08-14-2025
- BNC 09-16-2025
- Dividend Yield
- CLRB N/A
- BNC N/A
- EPS Growth
- CLRB N/A
- BNC N/A
- EPS
- CLRB N/A
- BNC N/A
- Revenue
- CLRB N/A
- BNC $3,478,254.00
- Revenue This Year
- CLRB N/A
- BNC N/A
- Revenue Next Year
- CLRB N/A
- BNC N/A
- P/E Ratio
- CLRB N/A
- BNC N/A
- Revenue Growth
- CLRB N/A
- BNC 10.08
- 52 Week Low
- CLRB $4.11
- BNC $5.60
- 52 Week High
- CLRB $67.50
- BNC $82.88
- Technical
- Relative Strength Index (RSI)
- CLRB 51.74
- BNC N/A
- Support Level
- CLRB $4.43
- BNC N/A
- Resistance Level
- CLRB $5.08
- BNC N/A
- Average True Range (ATR)
- CLRB 0.40
- BNC 0.00
- MACD
- CLRB 0.10
- BNC 0.00
- Stochastic Oscillator
- CLRB 73.11
- BNC 0.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.